Type I interferon dysregulation and neurological disease

  title={Type I interferon dysregulation and neurological disease},
  author={Sarah L McGlasson and Alexa Jury and Andrew Jackson and David P J Hunt},
  journal={Nature Reviews Neurology},
Type I interferon is an essential component of the brain's innate immune defence, conferring protection against viral infection. Recently, dysregulation of the type I interferon pathway has been implicated in the pathogenesis of a spectrum of neuroinfectious and neuroinflammatory disorders. Underactivity of the type I interferon response is associated with a predisposition to herpes simplex encephalitis. Conversely, a group of 'interferonopathic' disorders, characterized by severe… 
Type I interferonopathies in pediatric rheumatology
Known defects responsible for type I interferonopathies will likely promote the development of targeted therapy for atypical, severe, early onset rheumatic diseases.
Mice defective in interferon signaling help distinguish between primary and secondary pathological pathways in a mouse model of neuronal forms of Gaucher disease
Although IFN signaling is the top elevated pathway in nGD, it is demonstrated that this pathway is not related to mouse viability and is consequently defined as a secondary pathology pathway.
Update on the pathogenesis of central nervous system lupus.
NPSLE encompasses a diverse phenotype with distinct pathogenic mechanisms, which could be targeted by novel therapies or repositioning of existing drugs, and novel neuroimaging techniques suggest alterations in brain perfusion and metabolism.
Microglia have a more extensive and divergent response to interferon‐α compared with astrocytes
It is found that under basal conditions, each cell type has a unique gene expression pattern reflective of its developmental origin and biological function, which suggests specialized roles for these cells in host defense and in the development of cerebral interferonopathy.
Microglia responses to interleukin‐6 and type I interferons in neuroinflammatory disease
Findational knowledge regarding the microglial response to IL‐6 and IFN‐I is now being used to devise therapeutic strategies to ameliorate neuroinflammation and promote repair: either through targeting microglia, or by targeting the reduction of CNS levels or downstream biological pathways of IL-6 or IFN-I.
Interferons in Pain and Infections: Emerging Roles in Neuro-Immune and Neuro-Glial Interactions
How type-I and type-II IFNs regulate pain and infection via neuro-immune modulations, with special focus on neuroinflammation and neuro-glial interactions is discussed, and distinct roles of type- I IFNs in the peripheral and central nervous system are highlighted.
Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in STAT2
Observations reveal an essential in vivo function of STAT2 in the regulation of human IFNα/β signaling, providing concrete evidence of the serious pathological consequences of unrestrained IFN α/β activity and supporting efforts to target this pathway therapeutically in IFN-associated disease.
A novel phosphoproteomic landscape evoked in response to type I interferon in the brain and in glial cells
In the mouse model for IFN-I-induced neurodegeneration, protein phosphorylation, rather than the proteome, aligned with the clinical hallmarks and pathological outcome, including impaired development, motor dysfunction and seizures.
Experimental Neuromyelitis Optica Induces a Type I Interferon Signature in the Spinal Cord
It is observed that I-IFN treated ENMO rats had spinal cord lesions with fewer T cells, macrophages/activated microglia and activated neutrophils, and less astrocyte damage than their vehicle treated counterparts, suggesting beneficial effects of I- IFN.
Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature.
Clinical and experimental findings provide evidence of a causal link between type I IFN and TMA, and recombinant type IIFN therapies should be stopped at the earliest stage in patients who develop this complication, with implications for risk mitigation.


Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling
It is demonstrated that aberrant sensing of nucleic acids can cause immune upregulation and heterozygous mutations in the cytosolic double-stranded RNA receptor gene IFIH1 (also called MDA5) cause a spectrum of neuroimmunological features consistently associated with an enhanced interferon state.
Type I interferonopathies: a novel set of inborn errors of immunity
  • Y. Crow
  • Medicine
    Annals of the New York Academy of Sciences
  • 2011
A group of conditions, including Aicardi–Goutières syndrome, spondyloenchondrodysplasia, and cases of systemic lupus erythematosus with complement deficiency, are discussed, in which an upregulation of type I interferons is apparently central to their pathogenesis.
Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration.
Transgenic mice generated that produce IFN-alpha1 chronically from astrocytes developed a progressive inflammatory encephalopathy, with marked calcium mineralization, meninoencephalitis, gliosis, and neurodegeneration, suggesting that IFn-alpha overproduction may be the primary factor initiating human diseases.
Nucleic acid‐mediated inflammatory diseases
A hypothesis that accumulation of intracellular nucleic acids occurs as a consequence of mutation in these enzymes and triggers an inflammatory response through activation of innate immune pattern recognition receptors is proposed.
Aicardi–Goutières syndrome and the type I interferonopathies
The molecular and cellular basis of the interferonopathies, their categorization, future treatment strategies and the insights they provide into normal physiology are discussed.
USP18 lack in microglia causes destructive interferonopathy of the mouse brain
This work identified the ubiquitin‐specific protease (Usp) 18 in white matter microglia that essentially contributes to microglial quiescence and establishes Usp18 as a new molecule preventing destructive microgliopathy.
Astrocytes produce interferon‐alpha and CXCL10, but not IL‐6 or CXCL8, in aicardi‐Goutières syndrome
Data indicate that astrocytes are the predominant cell type responsible for the production of IFNα and CXCL10 in AGS, and CxCL10 may act as the chemoattractantresponsible for the influx of activated lymphocytes into the brain.